SR-4835 is primarily used in research settings as a potent and selective inhibitor of the CDK12/CDK13 kinase enzymes. It plays a key role in studies related to DNA damage response and transcription regulation in cancer cells. Due to its ability to disrupt the repair of DNA breaks, especially in BRCA-mutated cancers, SR-4835 enhances the effectiveness of certain chemotherapeutic agents and PARP inhibitors, making it a valuable tool in exploring synthetic lethality strategies. Its application is largely focused on preclinical oncology research, particularly in developing new combination therapies for aggressive cancers such as ovarian, breast, and prostate cancers. The compound helps elucidate the role of CDK12/13 in tumor progression and therapy resistance, supporting the development of targeted cancer treatments.